media – Page 9 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Exercising just one or two days a week can also lead to long-term health benefits.

The latest research by Chinese scientists shows that people can achieve the health benefits of daily exercise by engaging in physical activities for moderate to vigorous intensity for 1 to 2 days a week, as long as the total duration is at least 150 minutes per week. This research report was published in the recent issue of the “American Heart Association Journal”. Dr. Li Zhihao, an epidemiologist from Southern Medical University in Guangzhou, said that engaging in 150 minutes of moderate to vigorous physical activity per week, whether concentrated in 1 to 2 days or spread out over time, can significantly reduce the risk of death from cardiovascular diseases, cancer, or other causes. Those who cannot schedule physical exercise every day can focus on high-intensity activities on weekends. This study provides reliable evidence that even occasional physical activity can bring long-term health benefits, making it easier for people to prioritize ...
- Source: drugdu
- 46
- May 8, 2025
Tecnosalud

Organiser：TECNOSALUD AREQUIPA Time：September 10th – 12th, 2025 address：Av. Javier Prado Este 4200, Santiago de Surco, Lima, Peru Exhibition hall：Jockey Plaza Product range: Medical Equipment & Devices: Diagnostic equipment and instruments, emergency equipment, respiratory devices, imaging equipment, dialysis equipment, etc. Medical Consumables: Bandages, gauze, endoscopes, staplers, etc. Dental Products: Dental diagnostic equipment, dental handpieces, periodontal examination systems, dental surgical equipment, dental anesthesia devices, periodontal materials, etc. Pharmaceuticals: Pharmaceuticals, anesthetics, raw materials, intermediates, biological agents, chemicals, health products, and dietary supplements, etc. Laboratory Products: Laboratory instruments and equipment, optical instruments, image analysis and processing systems, testing instruments and devices, laboratory renovation and upgrade technologies, consumables, and related software, etc. Others: Rehabilitation products and hospital furniture, physiotherapy, medical automation, environmental health, medical tourism services, medical consulting services, medical publications, etc. About Tecnosalud： The Tecnosalud Medical Exhibition in Lima, Peru, is the most renowned medical equipment exhibition in Peru. It showcases the ...
- Source: drugdu
- 58
- May 8, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 60
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

Large expansion of grassroots drug catalog On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor ...
- Source: drugdu
- 67
- May 7, 2025
【EXPERT Q&A】What regulations and guiding principles are there for OOS investigations in pharmaceutical enterprises?

Drugdu.com expert’s response: Pharmaceutical companies are required to adhere to a series of regulations and guidelines when conducting investigations into Out-of-Specification (OOS) results. These documents provide a clear framework for the investigation process, responsibility allocation, and subsequent handling. The specifics are as follows: I. Core Regulatory Requirements FDA Regulations 21 CFR Part 211: Clearly stipulates Current Good Manufacturing Practices (CGMP) for pharmaceutical production and quality control, mandating the recording and investigation of any laboratory results that do not meet quality standards. FDA 211.192: Requires thorough investigations into OOS results. Even if a batch is rejected due to OOS, it is still necessary to determine whether the result is associated with other drugs or batches. FDA 211.194: Specifies that written records of investigations must include conclusions and follow-up actions to ensure process traceability. China GMP (Revised 2010 Edition): Article 224 mandates that quality control laboratories establish operating procedures for investigating out-of-specification ...
- Source: drugdu
- 54
- May 7, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 60
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor illnesses not leaving the village and ...
- Source: drugdu
- 61
- May 7, 2025
ExpoMedical

Organiser：ExpoMedical Time：September 24-26, 2025 address：Av. Costanera R. Obligado and J. Salguero, Buenos Aires, Argentina Exhibition hall：Costa Salguero Exhibition Center Product range: Medical Equipment: Medical devices, electronic medical equipment, diagnostic instruments for various departments, testing instruments, medical optical instruments, X-ray equipment, imaging devices, scanning equipment, MRI machines, ultrasound diagnostic tools, clinical laboratory analysis instruments, hemodialysis equipment, dental equipment, anesthesia and respiratory devices, interventional diagnostic tools, dialysis equipment, etc. Medical Supplies: Disposable medical supplies, consumables, syringes, blood transfusion sets, sanitary napkins, band-aids, face masks, bandages, stethoscopes, medical ambulances, operating room supplies, scrubs, medical kits, gloves, various surgical knives, forceps, scissors, dental and orthopedic grinding/drilling tools, small electronic instruments, testing devices and accessories, orthopedic surgical technologies, medical beds, surgical and disinfection supplies, cleaning technologies, ambulance supplies, bandages, wound dressings, etc. First Aid Supplies: First aid equipment, emergency response devices, pharmaceutical products, medications, infusion solutions, disinfectants, blood derivatives, nutritional supplements, dermatological medications, veterinary ...
- Source: drugdu
- 65
- May 6, 2025
【EXPERT Q&A】What are the differences between the Class II filing and the Class III license for medical devices?

Drugdu.com expert’s response: Key Differences Between Class II Medical Device Filing and Class III Medical Device Licensing in China: Risk Tiers, Regulatory Approaches, Scope, Application Processes, and Oversight Intensity Medical devices in China are categorized into Class II (moderate risk) and Class III (high risk), with distinct regulatory frameworks governing their filing and licensing. Below is a detailed analysis of their disparities: I. Distinctions Between Class II Filing and Class III Licensing 1. Risk Tiers and Regulatory Approaches Class II Medical Devices: Risk Profile: Moderate risk, requiring stringent controls to ensure safety and efficacy. Regulatory Mechanism: Managed through a filing system, emphasizing post-market accountability. Class III Medical Devices: Risk Profile: High risk, with potential for severe health consequences. Regulatory Mechanism: Subject to pre-market licensing, necessitating rigorous pre-approval scrutiny. 2. Scope of Application Class II Medical Devices: Intended for extracorporeal prevention, diagnosis, monitoring, treatment, or alleviation of diseases. Examples include thermometers, sphygmomanometers, and hearing aids. Class ...
- Source: drugdu
- 71
- May 5, 2025
The “insulin leader” saw a 1150% surge in net profit

On April 25, Ganli Pharmaceutical, a leading insulin company, released its first quarter report for 2025, reporting an excellent performance with both revenue and net profit growing. According to the report, the company’s Q1 operating income reached 985 million yuan, a year-on-year increase of 75.76%; net profit attributable to shareholders of listed companies reached 312 million yuan, a year-on-year increase of 224.9%; net profit attributable to shareholders after deducting non-recurring items reached 215 million yuan, a year-on-year increase of 1150.2%. From the perspective of revenue structure, Gan & Lee Pharmaceuticals achieved significant growth in both domestic and overseas revenue, which jointly drove the increase in overall revenue. In the domestic market, Ganli Pharmaceuticals performed strongly, with sales revenue reaching 889 million yuan, an increase of 395 million yuan over the same period last year, a year-on-year increase of 80.07%. This is mainly due to the substantial increase in sales of ...
- Source: drugdu
- 76
- May 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.